Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com
Αρχειοθήκη ιστολογίου
-
►
2023
(391)
- ► Φεβρουαρίου (200)
- ► Ιανουαρίου (191)
-
►
2022
(2843)
- ► Δεκεμβρίου (161)
- ► Σεπτεμβρίου (219)
- ► Φεβρουαρίου (264)
- ► Ιανουαρίου (280)
-
►
2021
(5625)
- ► Δεκεμβρίου (231)
- ► Σεπτεμβρίου (345)
- ► Φεβρουαρίου (620)
-
►
2020
(2065)
- ► Δεκεμβρίου (535)
- ► Σεπτεμβρίου (222)
- ► Φεβρουαρίου (28)
-
►
2019
(9608)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (3791)
- ► Ιανουαρίου (3737)
-
►
2018
(69720)
- ► Δεκεμβρίου (3507)
- ► Σεπτεμβρίου (3851)
- ► Φεβρουαρίου (8116)
- ► Ιανουαρίου (7758)
-
►
2017
(111579)
- ► Δεκεμβρίου (7718)
- ► Σεπτεμβρίου (7549)
- ► Φεβρουαρίου (10753)
- ► Ιανουαρίου (10529)
-
►
2016
(16402)
- ► Δεκεμβρίου (7478)
- ► Φεβρουαρίου (900)
- ► Ιανουαρίου (1250)
-
▼
2015
(1869)
-
▼
Δεκεμβρίου
(1451)
-
▼
Δεκ 06
(50)
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: cytomegalovirus colitis in a patient treat...
- Letter: management of post-operative Crohn's disea...
- Editors' declarations of interest
- Letter: cytomegalovirus colitis in a patient treat...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: wide variation in faecal calprotectin valu...
- Letter: coffee consumption and gallstone disease –...
- Editorial: what can be done when infliximab stops ...
- Letter: management of post-operative Crohn's disea...
- Editorial: what can be done when infliximab stops ...
- Letter: prostaglandin E1 therapy with alprostadil ...
- ErbB2/HER2-Specific NK Cells for Targeted Therapy ...
- Changes in Receipt of Cancer Screening in Medicare...
- Prostaglandin E1 therapy with alprostadil and risk...
- Letter: coffee consumption and gallstone disease –...
- Letter: factors determining liver fibrosis – more ...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: cytomegalovirus colitis in a patient treat...
- Letter: management of post-operative Crohn's disea...
- Editors' declarations of interest
- Letter: cytomegalovirus colitis in a patient treat...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: wide variation in faecal calprotectin valu...
- Letter: coffee consumption and gallstone disease –...
- Editorial: what can be done when infliximab stops ...
- Letter: management of post-operative Crohn's disea...
- Editorial: what can be done when infliximab stops ...
- Letter: prostaglandin E1 therapy with alprostadil ...
- ErbB2/HER2-Specific NK Cells for Targeted Therapy ...
- Changes in Receipt of Cancer Screening in Medicare...
- Prostaglandin E1 therapy with alprostadil and risk...
- Letter: coffee consumption and gallstone disease –...
- Letter: factors determining liver fibrosis – more ...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
-
▼
Δεκ 06
(50)
-
▼
Δεκεμβρίου
(1451)
! # Ola via Alexandros G.Sfakianakis on Inoreader
Η λίστα ιστολογίων μου
Κυριακή 6 Δεκεμβρίου 2015
Prostaglandin E1 therapy with alprostadil and risk reduction in early hepatic cellular carcinoma after liver transplantation
from Pharmacology via ola Kala on Inoreader http://ift.tt/1LXA24s
via IFTTT
from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QpUC3Q
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Αρχειοθήκη ιστολογίου
-
►
2023
(391)
- ► Φεβρουαρίου (200)
- ► Ιανουαρίου (191)
-
►
2022
(2843)
- ► Δεκεμβρίου (161)
- ► Σεπτεμβρίου (219)
- ► Φεβρουαρίου (264)
- ► Ιανουαρίου (280)
-
►
2021
(5625)
- ► Δεκεμβρίου (231)
- ► Σεπτεμβρίου (345)
- ► Φεβρουαρίου (620)
-
►
2020
(2065)
- ► Δεκεμβρίου (535)
- ► Σεπτεμβρίου (222)
- ► Φεβρουαρίου (28)
-
►
2019
(9608)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (3791)
- ► Ιανουαρίου (3737)
-
►
2018
(69720)
- ► Δεκεμβρίου (3507)
- ► Σεπτεμβρίου (3851)
- ► Φεβρουαρίου (8116)
- ► Ιανουαρίου (7758)
-
►
2017
(111579)
- ► Δεκεμβρίου (7718)
- ► Σεπτεμβρίου (7549)
- ► Φεβρουαρίου (10753)
- ► Ιανουαρίου (10529)
-
►
2016
(16402)
- ► Δεκεμβρίου (7478)
- ► Φεβρουαρίου (900)
- ► Ιανουαρίου (1250)
-
▼
2015
(1869)
-
▼
Δεκεμβρίου
(1451)
-
▼
Δεκ 06
(50)
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: cytomegalovirus colitis in a patient treat...
- Letter: management of post-operative Crohn's disea...
- Editors' declarations of interest
- Letter: cytomegalovirus colitis in a patient treat...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: wide variation in faecal calprotectin valu...
- Letter: coffee consumption and gallstone disease –...
- Editorial: what can be done when infliximab stops ...
- Letter: management of post-operative Crohn's disea...
- Editorial: what can be done when infliximab stops ...
- Letter: prostaglandin E1 therapy with alprostadil ...
- ErbB2/HER2-Specific NK Cells for Targeted Therapy ...
- Changes in Receipt of Cancer Screening in Medicare...
- Prostaglandin E1 therapy with alprostadil and risk...
- Letter: coffee consumption and gallstone disease –...
- Letter: factors determining liver fibrosis – more ...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: cytomegalovirus colitis in a patient treat...
- Letter: management of post-operative Crohn's disea...
- Editors' declarations of interest
- Letter: cytomegalovirus colitis in a patient treat...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Letter: wide variation in faecal calprotectin valu...
- Letter: coffee consumption and gallstone disease –...
- Editorial: what can be done when infliximab stops ...
- Letter: management of post-operative Crohn's disea...
- Editorial: what can be done when infliximab stops ...
- Letter: prostaglandin E1 therapy with alprostadil ...
- ErbB2/HER2-Specific NK Cells for Targeted Therapy ...
- Changes in Receipt of Cancer Screening in Medicare...
- Prostaglandin E1 therapy with alprostadil and risk...
- Letter: coffee consumption and gallstone disease –...
- Letter: factors determining liver fibrosis – more ...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
- Ibrutinib as Initial Therapy for Patients with Chr...
- Targeting BCL2 with Venetoclax in Relapsed Chronic...
-
▼
Δεκ 06
(50)
-
▼
Δεκεμβρίου
(1451)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου